Aller au contenu principal
Accès ouvert déclaré 2025 article

The Advanced Lung Cancer Inflammation Index: A Powerful and Independent Prognostic Factor in Metastatic Gastric Cancer

1Citations signalées, ce qui n’est pas une note de qualité
1Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Background and Objectives: The Advanced Lung Cancer Inflammation Index (ALI), a composite marker integrating body mass index (BMI), serum albumin, and neutrophil-to-lymphocyte ratio (NLR), has demonstrated prognostic value in various cancers. However, its role in metastatic gastric cancer (mGC) remains unexplored. This study aimed to investigate the prognostic significance of the ALI in patients with mGC. Materials and Methods: This retrospective study included 206 patients with de novo or recurrent metastatic gastric cancer treated at Manisa Celal Bayar University between September 2009 and 2024. The ALI was calculated as “BMI × serum albumin (g/dL)/NLR”. A cut-off value of 20.8 was determined using Receiver Operating Characteristic (ROC) curve analysis. Patients were stratified into high (ALI > 20.8) and low (ALI ≤ 20.8) groups. Survival outcomes were evaluated using Kaplan–Meier analysis, and prognostic factors were examined with Cox regression models. Results: The median overall survival (OS) was significantly longer in the high-ALI group compared to the low-ALI group (11.4 months vs. 5.2 months, p < 0.001). The 1-year and 2-year OS rates were 42.9% and 11.3% for the high-ALI group, versus 11.6% and 2.1% for the low-ALI group, respectively. Multivariate Cox regression analysis confirmed that a low ALI was an independent predictor of poorer survival (HR: 2.07, 95% CI: 1.47–2.92, p < 0.001). The low-ALI group also had a higher prevalence of peritoneal metastases and a lower likelihood of receiving first- and second-line chemotherapy. Conclusions: The ALI is a strong and independent prognostic factor for survival in patients with metastatic gastric cancer. As an easily calculable and cost-effective index derived from routine parameters, it shows significant potential for risk stratification and treatment planning in clinical practice. Prospective, multi-centre studies are warranted to validate these findings.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
The Advanced Lung Cancer Inflammation Index: A Powerful and Independent Prognostic Factor in Metastatic Gastric Cancer
Date Crossref
30/10/2025
Éditeur
MDPI AG
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Manisa Celal Bayar University pays non établi dans la notice
    Université ou école supérieure
  • Faculty of Medicine Department of Medical Oncology pays non établi dans la notice
    Université ou école supérieure

Manisa Celal Bayar University et Department of Medical Oncology — Faculty of Medicine.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Inflammatory Biomarkers in Disease PrognosisGastric Cancer Management and OutcomesMetastasis and carcinoma case studies

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.